Poor penetration of anticancer drugs into solid tumors, including breast cancer, is often a significant barrier to their anticancer efficacy. BRM131, represents a recombinant protein based on the adenovirus serotype 3 fiber knob that targets an epithelial junction opener and has the potential to address this issue. The recombinant protein binds to a specific receptor on tumor cells and opens tight junctions in solid tumors like breast cancer. This allows for improved penetration of therapeutics such as trastuzumab into the tumor and potentially increases tumor cell killing when compared to therapeutic alone.
BRM131 MOA Video